Excited to see our work come to life!

Fueling CAR with IL-9 bit.ly/4ox164C  @msofiacastelli

IL-9, the little-known cytokine, finally found its calling, helping CAR T cells take on solid tumors. More staying power, more memory, more punch. #science #immunology cell.com/immunity/abstract/S…

New in @ImmunityCP: @msofiacastelli and a team in the @carlhjune lab engineered CAR T cells with IL-9 signaling to boost efficacy against #SolidTumors. bit.ly/48vJql0

IL-9 signaling redirects CAR T cell fate toward CD8 memory and CD4 cycling states, enhancing antitumor efficacy: Immunity ⁦@parkerici⁩ ⁦@PennMedicine⁩ cell.com/immunity/abstract/S…

Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP cell.com/immunity/fulltext/S… cell.com/immunity/fulltext/S…

Report of note: IL-9 signaling redirects CAR T cell fate toward CD8 memory and CD4 cycling states, enhancing antitumor efficacy •Engineering CAR T cells with IL-9 signaling boosts efficacy against solid tumors •IL-9-signaling CD4 CAR T cells have increased Th1 and proliferative phenotypes •Single-cell profiling reveals that IL-9 redirects CD8 T cell fate away from dysfunction •IL-9-induced STAT1/STAT4 activation contributes to improved CAR T cell function cell.com/immunity/fulltext/S…

Online now: IL-9 signaling redirects CAR T cell fate toward CD8 memory and CD4 cycling states, enhancing antitumor efficacy dlvr.it/TPPKLL

IL-9 enhancement of engineered CAR-T therapies @ImmunityCP @carlhjune @msofiacastelli @Penn @xrtcell @stanford @KaylaKulhanek cell.com/immunity/fulltext/S… cell.com/immunity/fulltext/S…

🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation @PennMedicine antionbio.com @FrontiersIn frontiersin.org/journals/imm…

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. @carlhjune (@PennPathLabMed) & Jakub Svoboda (@PennCancer) @UPenn_I3H tinyurl.com/3ejw9334

Congratulations to our own Drs. June and Levine!

Penn researchers found that next-generation IL18-armored #CARTCellTherapy shows promise for patients whose #lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. @carlhjune @NEJM @AACR #NCRM #UnitedByCancerResearch spr.ly/6019NpiON

CAR T-cell therapy isn’t just a breakthrough—it’s a lifeline. A new PICI-supported review in @MolTherapy by @carlhjune, Director of the PICI Center at @PennMedicine, and team traces the decades of research that made engineered immune cells a powerful cancer treatment. cell.com/molecular-therapy-f…

CAR T-cell therapy has transformed treatment for 35K patients, with a well-established safety profile. New in @TheLancet: @carlhjune, Director of the PICI Center at @PennMedicine, @BLLPHD & @daniel_baker_j explore latest data and what’s next in the field. thelancet.com/journals/lance…

Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: brnw.ch/21wR0gf @parkerici @PennMedicine

Excited to share my PhD thesis work with @CarlHJune now out as a preprint on bioRxiv! We show that engineering IL-9 signaling enhances CAR T cell antitumor efficacy by steering them toward potent memory and effector states. biorxiv.org/content/10.1101/…